Lantheus控股 LNTH 深 滬
已收盤 04-02 16:00:00 美东时间
76.10
+0.400
+0.53%
華盛通- 最 高76.825
- 今 開75.07
- 成交量 42.25万股
- 最 低 74.64
- 昨 收 75.70
- 總市值 49.44亿
- 52周最高 108.91
- 市盈率 靜 22.30
- 換手率 0.65%
- 52周最低 47.25
- 委 比 98.36%
- 總股本 6497.16万
- 歷史最高 126.8899
- 量 比 0.59
- 振 幅 2.89%
- 歷史最低 1.76
- 每 手 1
- 風險率 14.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BUZZ-Lantheus falls as FDA extends review of experimental cancer diagnostic
BUZZ-Lantheus falls as FDA extends review of experimental cancer diagnostic ** Shares of drugmaker Lantheus Holdings LNTH.O fall 1.1% to $80.79 ** Co on Tuesday said the FDA extended its review of LNTH‑2501, an experimental radioactive diagnostic for cancer, by three months ** Co's LNTH‑2501 is desi
03-18 21:40
Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)
The US FDA has extended its review of Lantheus's LNTH-2501 (Gallium 68 edotreotide) NDA by three months to June 29, 2026 to allow additional time to evaluate manufacturing-related information. The extension does not affect the drug's efficacy or safety. LNTH-2501 is a radioactive diagnostic kit under evaluation for PET imaging of somatostatin receptor positive neuroendocrine tumors, supplied as a 2-vial kit to radiopharmacies. It is currently not...
03-17 20:01
Korn Ferry, Hewlett Packard Enterprise And 3 Stocks To Watch Heading Into Monday
U.S. stock futures up, Korn Ferry, ZIM, Lantheus, HPE, and Caseys General Stores in focus for earnings. Check out premarket coverage.
03-09 14:43
美股大行评级 | 花旗：维持康菲石油"买入"评级！目标价从125美元升至135美元
今日重点评级关注：HC Wainwright & Co.：维持Helus Pharma"买入"评级，目标价从55美元升至95美元；HC Wainwright & Co.：维持Compass Pathways"买入"评级，目标价从40美元升至70美元
03-03 20:22
BRIEF-Lantheus Receives FDA Tentative Approval For Lutetium Lu 177 Dotatate (Pnt2003), Radioequivalent To Lutathera®
BRIEF-Lantheus Receives FDA Tentative Approval For Lutetium Lu 177 Dotatate (Pnt2003), Radioequivalent To Lutathera® March 2 (Reuters) - Lantheus Holdings Inc LNTH.O : LANTHEUS RECEIVES FDA TENTATIVE APPROVAL FOR LUTETIUM LU 177 DOTATATE (PNT2003), RADIOEQUIVALENT TO LUTATHERA® Source text: ID:nGNX9
03-02 21:31
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
Lantheus Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate (PNT2003), Radioequivalent to LUTATHERA®
Lantheus Holdings announced FDA tentative approval for PNT2003, a radioequivalent version of LUTATHERA, for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This marks an important advancement in expanding treatment options for patients with GEP-NETs, as highlighted by CEO Mary Anne Heino. The approval follows a licensing agreement with POINT Biopharma Global, which was acquired by Eli Lilly...
03-02 13:30
Jones Trading Downgrades Lantheus Holdings to Hold
Jones Trading analyst Justin Walsh downgrades Lantheus Holdings (NASDAQ:LNTH) from Buy to Hold.
02-27 21:00
Lantheus Earnings Call Maps Painful Reset Before 2027
Lantheus Holdings Inc (($LNTH)) has held its Q4 earnings call. Read on for the ...
02-27 08:20
财报速睇 | Lantheus控股 2025财年年度营收15.42亿美元，同比增长0.5%；归母净利润2.34亿美元，同比下滑25.2%
华盛资讯2月26日讯，Lantheus控股公布2025财年年度业绩，公司年度营收15.42亿美元，同比增长0.5%，归母净利润2.34亿美元，同比下滑25.2%。
02-26 21:22
